Paediatric retinal dysfunction linked to high vigabatrin doses

Article

Paediatric retinal dysfunction may be linked to exposure to high daily doses of vigabatrin.

Paediatric retinal dysfunction may be linked to exposure to high daily doses of vigabatrin, reveals a study in the Journal of Paediatric Ophthalmology and Strabismus.

Dr Ulrika Kjellstrom and her team, Department of Ophthalmology, University of Lund, Sweden, investigated the full-field electroretinographies (ff-ERG) of 14 children who were administered vigabatrin.

Drug dosage parameters were compared in all participants, along with the ff-ERGs from healthy controls and were grouped according to age.

For the isolated rod response, combined rod-cone response and the 30 Hz flicker response there was reduced b-wave amplitudes. In 57% of the children who received vigabatrin there were significant changes in ff-ERG. The study showed no differences in cumulative doses or duration of medication.

The study suggests that careful follow-up should be performed for children who are administered vigabatrin, as high doses are linked to retinal dysfunction and photoreceptor damage.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.